A M Gotto

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi Cholesterol management in theory and practice
    A M Gotto
    Cornell University Medical College, New York, NY 10021, USA
    Circulation 96:4424-30. 1997
  2. ncbi Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting
    A M Gotto
    Cornell University Medical College, New York, NY 10021, USA
    Circulation 99:E1-7. 1999
  3. ncbi Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    A M Gotto
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Circulation 101:477-84. 2000
  4. ncbi Ongoing clinical trials of statins
    A M Gotto
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Cardiol 88:36F-40F. 2001
  5. ncbi How do we achieve optimal cardiovascular risk reduction?
    A M Gotto
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cardiol 24:III8-12. 2001
  6. ncbi Statin therapy: where are we? Where do we go next?
    A M Gotto
    Weill Medical College of Cornell University, Cornell University, New York, New York 10021, USA
    Am J Cardiol 87:13B-18B. 2001
  7. ncbi Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor
    Z Huang
    Department of Pathology, Center of Vascular Biology, Weill Cornell Medical College, New York, NY 10065, USA
    Br J Pharmacol 155:596-605. 2008
  8. ncbi High-density lipoprotein cholesterol: an updated view
    A M Gotto
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Opin Pharmacol 1:109-12. 2001
  9. ncbi Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    A M Gotto
    Joan and Sanford I Weill Medical College of Cornell University, 445 E 69th St, OH205, New York, NY 10021, USA
    Atheroscler Suppl 8:3-8. 2007
  10. ncbi Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women
    M Clearfield
    The University of North Texas Health Science Center, Fort Worth, Texas, USA
    J Womens Health Gend Based Med 10:971-81. 2001

Collaborators

  • J Han
  • D J Watson
  • S M Grundy
  • Christie Ballantyne
  • Haruo Nakamura
  • HENRY POWNALL
  • J Shepherd
  • S Oikawa
  • Evan Stein
  • Frank Sacks
  • A C Nicholson
  • Z Huang
  • D P Hajjar
  • X Zhou
  • Y Matsuzawa
  • J R Downs
  • M Clearfield
  • A J Marian
  • H Elghannam
  • W Kruyer
  • A Langendorfer
  • S Weis
  • S Turban
  • D R Shapiro
  • P A Beere
  • E J Whitney
  • S Lutucuta
  • L Ferlic
  • J Sasaki
  • T Kita
  • W He
  • V Zagrebelsky
  • H A Tyroler
  • R Brugada
  • F Fuentes
  • S Tavackoli
  • C Y Yang
  • D A Sparrow
  • J T Sparrow
  • S H Chen
  • B R Lee
  • P M Laplaud
  • M J Chapman
  • L Chan
  • D Bauchart
  • C F Wei
  • W H Li
  • S Auboiron
  • G Ghiselli
  • M Tanimura
  • Y L Marcel
  • Y Beigel
  • T Yang
  • R W Milne
  • D Setzer
  • S A Weng
  • T W Kim
  • S Krishnan
  • M L Yang
  • P F Chen

Detail Information

Publications22

  1. ncbi Cholesterol management in theory and practice
    A M Gotto
    Cornell University Medical College, New York, NY 10021, USA
    Circulation 96:4424-30. 1997
    ..It is imperative to prevent any reduction in public focus on primary and secondary prevention...
  2. ncbi Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting
    A M Gotto
    Cornell University Medical College, New York, NY 10021, USA
    Circulation 99:E1-7. 1999
    ..The hypothesis-based findings of 4S, CARE, and WOSCOPS support current clinical guidelines, and lowering LDL-C may reduce risk more substantially than might have been predicted...
  3. ncbi Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    A M Gotto
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Circulation 101:477-84. 2000
    ..This article describes the relation between baseline and on-treatment lipid and apolipoprotein (apo) parameters and subsequent risk for AMCEs...
  4. ncbi Ongoing clinical trials of statins
    A M Gotto
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Cardiol 88:36F-40F. 2001
    ..These trials are expected to yield important data on the relation of lipid reduction to the prevention of coronary artery disease and on the potential for extending the use of statins...
  5. ncbi How do we achieve optimal cardiovascular risk reduction?
    A M Gotto
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cardiol 24:III8-12. 2001
    ..Although intensified treatment is recommended for high-risk patients, cost considerations may limit drug therapy for some lower-risk individuals...
  6. ncbi Statin therapy: where are we? Where do we go next?
    A M Gotto
    Weill Medical College of Cornell University, Cornell University, New York, New York 10021, USA
    Am J Cardiol 87:13B-18B. 2001
    ..Challenges for future treatment guidelines include incorporation of emerging and novel risk factors into risk assessment, refinement of global risk measurement, and simplification for application to clinical practice...
  7. ncbi Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor
    Z Huang
    Department of Pathology, Center of Vascular Biology, Weill Cornell Medical College, New York, NY 10065, USA
    Br J Pharmacol 155:596-605. 2008
    ..Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARalpha) ligand, belongs to a drug class used to treat dyslipidaemic patients. We have investigated the effects of fenofibrate on hepatic LDLR expression...
  8. ncbi High-density lipoprotein cholesterol: an updated view
    A M Gotto
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Opin Pharmacol 1:109-12. 2001
    ..Recent studies indicate a benefit in treating patients with low levels of high-density lipoprotein cholesterol and suggest new clinical recommendations...
  9. ncbi Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    A M Gotto
    Joan and Sanford I Weill Medical College of Cornell University, 445 E 69th St, OH205, New York, NY 10021, USA
    Atheroscler Suppl 8:3-8. 2007
    ..On treatment, ApoB and ApoA1 were the best predictors. Based on AFCAPS/TexCAPS, a simple heuristic could be that individuals with "age plus one other risk factor" may benefit from statin therapy in primary prevention...
  10. ncbi Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women
    M Clearfield
    The University of North Texas Health Science Center, Fort Worth, Texas, USA
    J Womens Health Gend Based Med 10:971-81. 2001
    ..Lovastatin treatment was associated with statistically significant decreases in LDL-C and increases in HDL-C, and chronic long-term treatment with 20-40 mg/day lovastatin was well tolerated in women...
  11. ncbi A trilogy of primary prevention statin trials. Panel discussion
    Y Matsuzawa
    Sumitomo Hospital, Osaka, Japan
    Atheroscler Suppl 8:19-24. 2007
    ..Japanese physicians tend to use small doses of statin and believe that these are effective in lowering cholesterol sufficiently with few side effects and encourage good compliance...
  12. ncbi Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin
    J R Downs
    Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, USA
    Am J Cardiol 87:1074-9. 2001
    ....
  13. ncbi Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression
    A C Nicholson
    Department of Pathology, Center of Vascular Biology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Br J Pharmacol 151:807-15. 2007
    ..These studies may have implications in the regulation of adipogenesis in response to statins...
  14. ncbi Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy
    S Lutucuta
    Sections of Cardiology and Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Circ Res 88:969-73. 2001
    ..001). No association between the genotypes and progression of coronary atherosclerosis or clinical events was detected. We conclude that ABCA1 genotypes are potential risk factors for coronary atherosclerosis in the general population...
  15. ncbi A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin
    S Turban
    Department of Medicine, Sections of Cardiology and Atherosclerosis, Baylor College of Medicine, Houston, TX 77030, USA
    Atherosclerosis 154:633-40. 2001
    ..Thus, the Q/R192 polymorphism is not a major risk factor in susceptibility to CAD in the LCAS population...
  16. ncbi A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy
    H Elghannam
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    J Mol Med (Berl) 78:562-8. 2000
    ....
  17. ncbi The complete cDNA and amino acid sequence of human apolipoprotein B-100
    S H Chen
    J Biol Chem 261:12918-21. 1986
    ..Our findings on apoB structure provide a basis for future experimentation on the role of apoB-100-containing lipoproteins in atherosclerosis...
  18. ncbi Plasma metabolism of apolipoprotein A-IV in humans
    G Ghiselli
    J Lipid Res 27:813-27. 1986
    ....
  19. ncbi The primary structure of apolipoprotein A-I from rabbit high-density lipoprotein
    C Y Yang
    Eur J Biochem 160:427-31. 1986
    ..This suggests that the N-terminal half of apo A-I contains the major portion of regions activating lecithin: cholesterol acyltransferase...
  20. ncbi Molecular cloning and expression of partial cDNAs and deduced amino acid sequence of a carboxyl-terminal fragment of human apolipoprotein B-100
    C F Wei
    Proc Natl Acad Sci U S A 82:7265-9. 1985
    ..Our findings on apoB structure might be important for understanding the role of apoB-100-containing lipoproteins in atherosclerosis...
  21. ncbi Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100
    C Y Yang
    Baylor College of Medicine, Houston, TX
    Proc Natl Acad Sci U S A 87:5523-7. 1990
    ..We propose a linear model of apolipoprotein B-100 in low density lipoprotein that wraps around the low density lipoprotein molecule...
  22. ncbi Plasma lipid transport in the preruminant calf, Bos spp: primary structure of bovine apolipoprotein A-I
    D A Sparrow
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030
    Biochim Biophys Acta 1123:145-50. 1992
    ..Finally, comparison of sequence homology between bovine apoA-I and the lecithin:cholesterol acyl transferase (LCAT) activating region of human apoC-I suggests that several LCAT activating domains may be present in calf apoA-I...